Gebbia V, Carreca I, Testa A, Valenza R, Curto G, Cannata G, Borsellino N, Latteri M A, Cipolla C, Florena M
University of Palermo, Chair and Service of Chemotherapy, Italy.
Anticancer Drugs. 1993 Aug;4(4):443-5. doi: 10.1097/00001813-199308000-00004.
Forty patients with chemotherapy-related diarrhea were randomized to receive (i) octreotide 0.5 mg three times per day s.c. or (ii) loperamide 4 mg three times per day p.o. until complete remission of diarrhea was achieved. In the octreotide group 80% of patients showed complete resolution of loose bowel movements within 4 days of therapy, while in the loperamide group this goal was obtained in only 30% of cases (p < 0.001). If after 4 days no benefit was seen, patients were considered to have failed antidiarrheal therapy. Failure was recorded in only one case (5%) treated with s.c. octreotide and in five patients (25%) who received loperamide. The mean duration of antidiarrheal therapy necessary to achieve remission was 3.4 days in the octreotide group and 6.1 days in the loperamide group (p < 0.001). Treatment with octreotide was very well tolerated with mild abdominal pain in 15% of cases and pain in the injection site in 15% of patients. Subcutaneous octreotide is highly effective in the management of chemotherapy-related diarrhea in cancer patients.
40例化疗相关性腹泻患者被随机分为两组，分别接受：(i) 奥曲肽0.5毫克，皮下注射，每日3次；或(ii) 洛哌丁胺4毫克，口服，每日3次，直至腹泻完全缓解。在奥曲肽组中，80%的患者在治疗4天内腹泻完全缓解，而在洛哌丁胺组中，只有30%的病例达到这一目标（p<0.001）。如果4天后未见疗效，则认为止泻治疗失败。皮下注射奥曲肽治疗的患者中仅1例（5%）治疗失败，接受洛哌丁胺治疗的患者中有5例（25%）治疗失败。奥曲肽组达到缓解所需的止泻治疗平均持续时间为3.4天，洛哌丁胺组为6.1天（p<0.001）。奥曲肽治疗耐受性良好，15%的患者出现轻度腹痛，15%的患者注射部位疼痛。皮下注射奥曲肽在治疗癌症患者化疗相关性腹泻方面非常有效。
